Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

@article{Jubb2010BiomarkersTP,
  title={Biomarkers to predict the clinical efficacy of bevacizumab in cancer.},
  author={Adrian M. Jubb and Adrian L. Harris},
  journal={The Lancet. Oncology},
  year={2010},
  volume={11 12},
  pages={1172-83}
}
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangiogenic activity and improves progression-free survival in many solid malignancies when combined with cytotoxic chemotherapy, but has little effect on overall survival. Despite the effects of this drug in unselected patients, the Response Evaluation Criteria in Solid Tumours are suboptimum to predict benefit. Additionally, tumours show inherent and emerging resistance to regimens that include… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 139 extracted citations

Similar Papers

Loading similar papers…